Sri Sri Ravi Shankar launches Tattva 'drug-combo' to Prevent COVID-19

The 'drug-combo' by Sri Sri Ravi Shankar's Tattva is a combination of Ayurvedic and Siddha medicines, to prevent and treat the deadly COVID-19 virus
Sri Sri Ravi Shankar launches Tattva 'drug-combo' to Prevent COVID-19

New Delhi: Sri Sri Ravi Shankar has recently claimed that his "Tattva" has formulated combinations of Ayurvedic and Siddha medicines, which can help to prevent the COVID-19. His company has tested the drug combo for anti-inflammatory and immune-boosting Ayurvedic agent and their effectiveness against the COVID-19. This has been carried out under the guidance of Frankfurt Innovation Centre fo Biotechnology.

Sri Sri Ravi Shankar's  coronavirus medicine Tattva can be used for the prevention & treatment of COVID-19.

However, no such medicine has been developed which has proved to cure the disease.

Earlier this year, Baba Ramdev's Patanjali claimed to develop an ayurvedic medicine which cured the disease.

The medicines by Tattva has been given to Delhi's AYUSH department for the treatment and prevention of COVID-19. It is also being distributed for prophylactic (prevention) care in Tamil Nadu.

Siddha formulation tablet, Kabasur Kudineer was tested for screening inhibitors of the COVID-19 virus. The tablets were strongest in preventing the entry of the virus into the human cells, said Tattva in their statement.

The company's press release also said that Amruth and Immugen also had similar inhibitory effects, which is 60-65 per cent and 80 per cent respectively. Tattva also shared their other studies, which were done on herbal products. They claimed that a few products boosted one's immunity against the COVID-19.

The company also carried out a second clinical trial in Bengaluru's Narayana Hrudayalaya Hospital. It said that medicine does not have any side effect or negative effect on the patient. However, there was no proven positive effect too.

A third and final study was conducted at Bangalore Medical College and Research Institute (BMCRI). It was conducted among 96 healthcare workers who were working in the COVID-19 wards. This was carried out to evaluate or analyse the immune-modulating properties of herbal medicines.

Top Headlines

No stories found.
Sentinel Assam
www.sentinelassam.com